Foundation Medicine® is a world-leading molecular insights company that is making precision medicine a reality for thousands.11
Our Services
Our comprehensive genomic profiling approach broadly analyses the tumour genome to identify clinically-relevant genomic alterations and potentially expand patients’
treatment options.1-5
A comprehensive approach to genomic profiling
Our comprehensive genomic profiling approach analyses known cancer-relevant genes as well as tumour mutational burden (TMB)† and microsatellite instability (MSI)† in a single test.1,7,9,12,13
Genomic insights that support clinical decision-making
A clear, in-depth report provides insights on a patient’s genomic profile as well as associated targeted therapies, immunotherapies and relevant clinical trials.14
A high-quality portfolio of services
Our high-quality portfolio of comprehensive genomic profiling* services helps optimise and personalise treatment pathways for patients in diverse clinical situations.7-10
About Us
As part of our long-standing commitment to pioneering progress in precision medicine, Roche is collaborating with molecular insights leader Foundation Medicine.11 Through this combination Roche is making Foundation Medicine's comprehensive genomic profiling services available to patients outside of the United States. This collaboration combines Roche’s expertise and commitment in oncology with Foundation Medicine’s leading technology, validation, and experience in cancer profiling.11
Ordering
To order a test, start by selecting your country of residence.
Need More Details?
We're committed to excellent service. If you have questions or need assistance, our client services team is available to help.
*Comprehensive genomic profiling is a tumour testing method that utilises next generation sequencing technology to identify all four classes of alterations across a large set of cancer-related genes (>50) known to drive cancer across tumour types. Comprehensive genomic profiling is a ‘pan-tumour’ approach, or applicable for use across any type of cancer.
†TMB reported in FoundationOne®CDx and FoundationOne®Heme. MSI reported in FoundationOne CDx, FoundationOne®Liquid and FoundationOne Heme.